Solara Active Pharma Sciences
BSE 541540
12 stories, newest first.
- Q2 FY27 call: revenue up 33% to INR418 crores, PAT INR28.5 crores; Ibuprofen review to close in 12 weeks
- Final reminder-cum-forfeiture notice sent to holders of partly paid-up shares
- Monitoring Agency Report: no deviation in Rights Issue proceeds utilisation
- Solara Active Pharma uploads audio recording of Q2 FY27 earnings call held October 16, 2026
- Grant of 4.7 lakh options under ESOP 2024 at Rs. 375 per share
- Q2 FY27: revenue up 33% to INR 4,178 Mn, EBITDA up 118% to INR 769 Mn, PAT at INR 285 Mn
- Board approves unaudited Q2 and H1 results; auditor's review conclusion unmodified
- Solara Active Pharma Sciences to hold analysts/investors conference call on October 16, 2026 at 4:00 PM IST for Q2FY27 results
- ESG rating upgraded to Crisil ESG 63 under Strong category for FY26
- Rights Issue: Final Reminder-cum-Forfeiture Notice Approved for Unpaid Call Money
- Board meeting on October 16, 2026 to consider and approve September quarter results
- Reminder to Physical Shareholders to Submit PAN, KYC and Nomination Details
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.